华海药业(600521.SH)：注射用尼可地尔获得药品注册证书

Core Viewpoint - Huahai Pharmaceutical (600521.SH) has received the drug registration certificate for injectable Nicorandil from the National Medical Products Administration, marking a significant milestone for the company in the cardiovascular drug market [1] Company Summary - The injectable Nicorandil is indicated for unstable angina and was originally developed by Chugai Pharmaceutical Co., Ltd., being launched in Japan in September 1993 [1] - Currently, the domestic market has several manufacturers with the drug registration certificate, including Beijing Four Rings Kebo Pharmaceutical Co., Ltd., Yangtze River Pharmaceutical Group Co., Ltd., and Tianjin Tianshili Zhiqiao Pharmaceutical Co., Ltd. [1] Industry Summary - According to data from Minai Network, the projected domestic market sales for injectable Nicorandil in 2024 are approximately RMB 620 million [1]